In biotech, sometimes it's the companies that aren't making a single dime that end up being the very best investments after a short time. For instance, Viking Therapeutics (NASDAQ: VKTX) doesn't yet have any revenue. But thanks to its ongoing clinical investigations and the high-quality data they're yielding, Viking shares have vaulted 347% in the last 12 months alone.

And that might just be the start. So if you're looking to make a relatively small investment of $1,000 in one stock that's on the riskier side, it's hard to park your cash in a more exciting and upwardly mobile biotech than Viking. Here's why.

While big-league competitors like Novo Nordisk and Eli Lilly currently dominate the weight loss market, that won't go on forever, most likely because Viking or one of its peers will break in with candidates of their own.

Continue reading

Source Fool.com